Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of LAXAI Life Sciences.

    Client Virtual Booth

    LAXAI LIFE SCIENCES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    LAXAI Life Sciences
    india-flag Flag
    Country
    Country
    India
    Address
    Address
    3rd Floor, Ventureast Plaza, Plot Nos. 40 & 41, Road Number 2, Financial District, Nanakramguda, Ranga Reddy District, Telangana 500032
    Telephone
    Telephone
    +91 40 6111 6888
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://laxai.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    CSIR in Partnership with Laxai Life Sciences has received Regulatory Approval to Begin Clinical Trials on Covid-19 Patients with Colchicine

    Details:

    CSIR and Laxai Life Sciences have been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of clinical outcomes during the treatment of COVID-19 patients.


    Lead Product(s): Colchicine,Niclosamide

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: CSIR-Indian Institute of Chemical Technology

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 12, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Phase II Clinical Trial of Niclosamide Drug for Treatment of Covid-19 Patients Begins

    Details:

    The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of NIclosamide for the treatment of hospitalized Covid-19 patients.


    Lead Product(s): Niclosamide

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: CSIR-Indian Institute of Chemical Technology

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 06, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    CSIR Seeks Regulatory Nod for Clinical Trials Using Combination of Antivirals and HDTs Against COVID-19

    Details:

    Study will combine and repurpose antivirals and host-directed therapies and to determine safety & efficacy of a combination of drugs (Favipiravir+Colchicine, Umifenovir+Colchicine and Nafamostat+5-ALA) and a control arm with the standard of care in COVID-19 patients.


    Lead Product(s): Favipiravir,Colchicine

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 08, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    A2A Pharmaceuticals Collaborates With LAXAI Life Sciences to Co-develop SARS-CoV-2 Main Proteases Inhibitors for the Treatment of COVID-19

    Details:

    Under this collaboration, A2A designed the molecules using its proprietary computational AI-enabled drug discovery platform SCULPT™, which are currently being synthesized and will be evaluated by Laxai.


    Lead Product(s): Undisclosed

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: LAXAI Life Sciences

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement June 08, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search